Applying scientific criteria to therapeutic interchange: A balanced analysis of low-molecular-weight heparins

被引：26
作者：
Merli, GJ
Vanscoy, GJ
Rihn, TL
Groce, JB
McCormick, W
机构：
[1] Thomas Jefferson Univ Hosp, Jefferson Med Coll, Philadelphia, PA 19107 USA
[2] Univ Pittsburgh, Pittsburgh, PA 15260 USA
[3] Duquesne Univ, Sch Pharm, Pittsburgh, PA 15219 USA
[4] Campbell Univ, Sch Pharm, Buies Creek, NC 27506 USA
来源：
JOURNAL OF THROMBOSIS AND THROMBOLYSIS | 2001年 / 11卷 / 03期
关键词：
low-molecular-weight heparins; therapeutic interchange; scientific criteria;
D O I：
10.1023/A:1011969005756
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Under pressure to provide cost-effective healthcare, many healthcare systems have adopted Therapeutic Interchange (TI) programs-the interchange of therapeutically equivalent but chemically unique drugs-to reduce the total cost of therapy without compromising patient care. To be appropriate and feasible, a TI program for any class of drugs must meet certain rigorous criteria and undergo medical, financial, tactical, and legal reviews. Moreover, once a TI program is implemented, a process to monitor its success should be established. Application of the TI criteria to low-molecular-weight heparins (LMWHs) reveals that a blanket TI program for LMWHs does not appear advisable at this time.
引用
收藏
页码：247 / 259
页数：13
相关论文
共 60 条
[1]  
*AC MAN CAR PHARM, 1996, MAN CAR PHARM FACTSH
[2]  
*ACCP, 2001, CHEST S, V119
[3]   Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery [J].
Agnelli, G ;
Piovella, F ;
Buoncristiani, P ;
Severi, P ;
Pini, M ;
D'Angelo, A ;
Beltrametti, C ;
Damiani, M ;
Andrioli, GC ;
Pugliese, R ;
Iorio, A ;
Brambilla, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (02) :80-85
[4]  
*AM MED ASS, 2000, H125991 AM MED ASS
[5]  
[Anonymous], AM J HOSP PHARM
[6]  
[Anonymous], J MANAG CARE PHARM
[7]   Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction - Results of the thrombolysis in myocardial infarction (TIMI) 11B trial [J].
Antman, EM ;
McCabe, CH ;
Gurfinkel, EP ;
Turpie, AGG ;
Bernink, PJLM ;
Salein, D ;
de Luna, AB ;
Fox, K ;
Lablanche, JM ;
Radley, D ;
Premmereur, J ;
Braunwald, E .
CIRCULATION, 1999, 100 (15) :1593-1601
[8]  
Bick RL, 1999, SEMIN THROMB HEMOST, V25, P97
[9]   Comparative effectiveness of low-molecular-weight heparins after therapeutic interchange [J].
Bollinger, KA ;
Vermeulen, LC ;
Davis, SN ;
Geurkink, EA .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (04) :368-372
[10]   Therapeutic interchange of low-molecular-weight heparins [J].
Burnakis, TG .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (19) :1797-1798
123456